According to a new study, dupilumab shows safety and efficacy for up to four years in treatment of moderate-to-severe atopic dermatitis (AD) in adults.
top of page
it's where dermatology lives
bottom of page
According to a new study, dupilumab shows safety and efficacy for up to four years in treatment of moderate-to-severe atopic dermatitis (AD) in adults.
Коментари